Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP significantly increased its stake in Kodiak Sciences by 163.6%, owning 205,833 shares after acquiring an additional 127,748 shares during the first quarter.
• Kodiak Sciences reported a quarterly earnings loss of $1.09 per share, missing the consensus estimate by $0.20.
• The company is currently focused on developing therapies for retinal diseases, with its lead product candidate in advanced clinical trials for conditions such as wet age-related macular degeneration.

GSA Capital Partners LLP lifted its position in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 163.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 205,833 shares of the company's stock after buying an additional 127,748 shares during the period. GSA Capital Partners LLP owned approximately 0.39% of Kodiak Sciences worth $577,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. The Manufacturers Life Insurance Company acquired a new position in Kodiak Sciences in the fourth quarter worth approximately $902,000. Vontobel Holding Ltd. bought a new stake in shares of Kodiak Sciences during the 1st quarter worth $28,000. Dimensional Fund Advisors LP grew its holdings in shares of Kodiak Sciences by 5.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 521,237 shares of the company's stock worth $5,186,000 after acquiring an additional 26,058 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Kodiak Sciences by 194.9% in the 4th quarter. JPMorgan Chase & Co. now owns 131,646 shares of the company's stock worth $1,310,000 after acquiring an additional 86,998 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its position in shares of Kodiak Sciences by 287.2% during the fourth quarter. Nantahala Capital Management LLC now owns 266,613 shares of the company's stock worth $2,653,000 after purchasing an additional 197,756 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Kodiak Sciences Stock Up 1.2%

Shares of NASDAQ KOD opened at $6.65 on Monday. Kodiak Sciences Inc. has a 12 month low of $1.92 and a 12 month high of $11.60. The company has a market cap of $350.85 million, a price-to-earnings ratio of -1.83 and a beta of 2.41. The business has a fifty day simple moving average of $4.61 and a 200-day simple moving average of $4.33.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). As a group, sell-side analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.